Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Careseng 1370 for Chemotherapy-Induced Myelosuppression in Advanced NSCLC
NCT03692780Phase 2Withdrawn
- Sponsor
- Careseng Biotech Co., Ltd.
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in myelosuppression comparing Careseng 1370 Arm with Placebo Arm (2 arms). Primary endpoint: Maximum change of absolute neutrophil count (ANC) at Day 85. Planned start Mar 2019; status: withdrawn.
02
Drugs
careseng
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT03692780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692780.